Charts for: – sales, costs, margins, earnings – current assets, long-term assets, liabilities, debt, equity – cash flows from operations,…
Merck (MRK): A little growth pill wouldn’t hurt the declining sales.
At least the cash flows from operating activities look healthy.
Merck Complete Financials Q2 2013.
The original MRK report for Q2 2013 is being updated here.
Conclusions are the same: sales declining, costs increasing, earnings down.
Pipeline is drying.
Merck Q2 2013: sales declining, costs increasing, earnings down.
RSS - Posts